Sialic acid-modified antigens impose tolerance via inhibition of T-cell proliferation and de novo induction of regulatory T cells by Perdicchio, Maurizio et al.
                                                              
University of Dundee
Sialic acid-modified antigens impose tolerance via inhibition of T-cell proliferation and
de novo induction of regulatory T cells
Perdicchio, Maurizio; Ilarregui, Juan M.; Verstege, Marleen I.; Cornelissen, Lenneke A M;
Schetters, Sjoerd T T; Engels, Steef; Ambrosini, Martino; Kalay, Hakan; Veninga, Henrike;
Den Haan, Joke M M; Van Berkel, Lisette A.; Samsom, Janneke N.; Crocker, Paul R.;
Sparwasser, Tim; Berod, Luciana; Garcia-Vallejo, Juan J.; Van Kooyk, Yvette; Unger, Wendy
W J
Published in:
Proceedings of the National Academy of Sciences of the United States of America
DOI:
10.1073/pnas.1507706113
Publication date:
2016
Document Version
Publisher's PDF, also known as Version of record
Link to publication in Discovery Research Portal
Citation for published version (APA):
Perdicchio, M., Ilarregui, J. M., Verstege, M. I., Cornelissen, L. A. M., Schetters, S. T. T., Engels, S., ... Unger,
W. W. J. (2016). Sialic acid-modified antigens impose tolerance via inhibition of T-cell proliferation and de novo
induction of regulatory T cells. Proceedings of the National Academy of Sciences of the United States of
America, 113(12), 3329-3334. DOI: 10.1073/pnas.1507706113
General rights
Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other
copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with
these rights.
 • Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
 • You may not further distribute the material or use it for any profit-making activity or commercial gain.
 • You may freely distribute the URL identifying the publication in the public portal.
Sialic acid-modified antigens impose tolerance via
inhibition of T-cell proliferation and de novo
induction of regulatory T cells
Maurizio Perdicchioa,1, Juan M. Ilarreguia, Marleen I. Verstegea, Lenneke A. M. Cornelissena, Sjoerd T. T. Schettersa,
Steef Engelsa, Martino Ambrosinia, Hakan Kalaya, Henrike Veningaa, Joke M. M. den Haana, Lisette A. van Berkelb,
Janneke N. Samsomb, Paul R. Crockerc, Tim Sparwasserd, Luciana Berodd, Juan J. Garcia-Vallejoa, Yvette van Kooyka,2,3,
and Wendy W. J. Ungera,3,4
aDepartment of Molecular Cell Biology and Immunology, VU University Medical Center, 1007 MB, Amsterdam, The Netherlands; bDepartment of Pediatrics,
Erasmus University Medical Center, 3000 CA, Rotterdam, The Netherlands; cDivision of Cell Signalling and Immunology, College of Life Sciences, University
of Dundee, Dundee DD15 EH, United Kingdom; and dInstitute for Infection Immunology, TWINCORE, 30625 Hannover, Germany
Edited by Harvey Cantor, Dana-Farber Cancer Institute, Boston, MA, and approved January 29, 2016 (received for review April 20, 2015)
Sialic acids are negatively charged nine-carbon carboxylated mono-
saccharides that often cap glycans on glycosylated proteins and lipids.
Because of their strategic location at the cell surface, sialic acids
contribute to interactions that are critical for immune homeostasis
via interactions with sialic acid-binding Ig-type lectins (siglecs). In
particular, these interactions may be of importance in cases where
sialic acids may be overexpressed, such as on certain pathogens
and tumors. We now demonstrate that modification of antigens
with sialic acids (Sia-antigens) regulates the generation of antigen-
specific regulatory T (Treg) cells via dendritic cells (DCs). Addition-
ally, DCs that take up Sia-antigen prevent formation of effector
CD4+ and CD8+ T cells. Importantly, the regulatory properties
endowed on DCs upon Sia-antigen uptake are antigen-specific:
only T cells responsive to the sialylated antigen become tolerized.
In vivo, injection of Sia-antigen–loaded DCs increased de novo
Treg-cell numbers and dampened effector T-cell expansion and
IFN-γ production. The dual tolerogenic features that Sia-antigen
imposed on DCs are Siglec-E–mediated and maintained under in-
flammatory conditions. Moreover, loading DCs with Sia-antigens
not only inhibited the function of in vitro–established Th1 and
Th17 effector T cells but also significantly dampened ex vivo myelin-
reactive T cells, present in the circulation of mice with experimental
autoimmune encephalomyelitis. These data indicate that sialic
acid-modified antigens instruct DCs in an antigen-specific tolero-
genic programming, enhancing Treg cells and reducing the gener-
ation and propagation of inflammatory T cells. Our data suggest
that sialylation of antigens provides an attractive way to induce
antigen-specific immune tolerance.
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Antigen-presenting cells (APCs), and predominantly den-dritic cells (DCs), are crucial to maintain immune homeo-
stasis, because these cells determine whether or not an immune
reaction is mounted against pathogens or self or innocuous foreign
antigens. In healthy individuals, encounter with innocuous (self-)
antigens will lead to induction of regulatory T (Treg) cells, which
in turn dampen excessive immune responses, a process that fails
in autoimmune patients (1).
Ways to promote this immune-inhibitory signature of DCs may
therefore provide new therapeutic strategies to fight autoimmune
disorders. Although different methods are described to push
DCs into an immune-inhibitory mode, none of these methods is
antigen-specific and may therefore exert off-target effects. Ad-
ditional evidence suggests that merely generating a large pool of
Treg cells is not sufficient to control aberrant immunity: the
inflammatory milieu in the affected areas promotes a strong
APC-mediated activation of antigen-specific autoreactive T cells,
which makes these autoreactive T cells refractory to suppression
by Treg cells (2–5). These findings suggest that strategies that
aim at controlling autoimmunity should not only involve inducing
Treg-cell populations but also dampening autoreactive T cells,
thereby creating a milieu that allows Treg cells to exert their
suppressive function. Certain pathogenic infections and tumors
are marked by the presence of tolerogenic DCs and T cells (6–9).
An often overlooked feature shared by these pathological con-
ditions is the presence of aberrant glycosylation patterns (7, 10–
12). In particular, increased levels of sialic acids have been dem-
onstrated in these situations. On tumors, enhanced sialylation
driven by enhanced expression and activity of β-galactoside
α2,6-sialyltransferase 1 (ST6Gal-1) and/or α-N-acetylgalactosa-
minide α2,6-sialyltransferase 1 (ST6GalNAc-I) often correlates
with tumor invasion and poor prognosis (13–15). Additionally, the
hypersialylated pathogens Campylobacter jejuni and Neisseria
meningitides were shown to negatively affect human APC function
and consequently subvert immune responses (7, 16–19).
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Sialic acids are the outermost monosaccharides on glycan
chains of glycoproteins and glycolipids, attached to the under-
lying glycans with α2,3, α2,6, or α2,8 linkage (14) and as such
form the recognition elements for sialic acid-binding Ig-like
lectins (siglecs) (14, 20). Siglecs are predominantly expressed by
innate immune cells, such as DCs, macrophages, and B cells (20).
On these cells, siglecs function as endocytic receptors as well
as can regulate activation status and cytokine secretion. Most
siglecs are characterized by the presence of one or more immu-
noreceptor tyrosine-based inhibitory motifs (ITIMs) in their in-
tracellular domain (21) and, thus, siglec triggering often counteracts
activatory signals elicited by receptors containing immunoreceptor
tyrosine-based activatory motifs (ITAMs) (20). Although engage-
ment of the hCD33rSiglecs on innate cells by sialylated antigens
has been shown to negatively modulate the proinflammatory func-
tions of APCs, effects on T-cell responses have not yet been in-
vestigated in detail.
Because the immune-inhibitory effects induced by sialylated
pathogens and tumors may be attributed to different configurations
of sialic acid-containing glycoproteins or glycolipids, we set out to
characterize the effects of sialic acids on DCs and T-cell responses
using a well-characterized neoglycoconjugate approach based on the
model antigens ovalbumin (OVA) or the encephalitogenic peptide
derived from myelin oligodendrocyte glycoprotein (MOG35–55)
that we modified with either α2,3- or α2,6-linked sialyl-lactose
(hereafter named Sia-antigens). Our data reveal that internali-
zation of Sia-antigen by DCs endows them with the ability to
promote the differentiation of naive CD4+ T cells into Treg cells
at the expense of functional CD4+ and CD8+ effector T cells,
both in vitro and in vivo. We provide evidence that this feature is
antigen-specific and even effective under inflammatory condi-
tions. Moreover, our findings demonstrate that Sia-antigen–
loaded DCs also dampen the function of established effector T
cells, suggesting that sialylation of antigens provides a means to
dampen excessive T-cell pathologies.
Results
Sia-Antigen–Pulsed DCs Promote de Novo Induction of Foxp3+CD4+
Treg Cells. Because hypersialylated tumors and pathogens have
been linked with tolerogenic DCs and T cells, we hypothesized
that sialic acids present on glycosylated antigens may serve as an
inhibitory signal and down-modulate inflammatory T-cell re-
sponses. To examine whether T-cell polarization is influenced by
DCs exposed to sialylated antigens, we generated neoglycoconjugates
by maleimide-thiol coupling of α2,3- or α2,6-linked sialyl-lactose to
either OVA (yielding α2,3- or α2,6-Sia-OVA, respectively, Fig. S1).
Subsequently, splenic CD11c+DCs were pulsed with α2,3- or α2,6-
Sia-OVA and cocultured with naive CD4+CD62LhiCD25−OT-II T
cells. In these DC–T-cell cocultures, the Sia-OVA–pulsed DCs
induced a two- to fivefold increase in Foxp3+CD4+ T-cell numbers
(Fig. 1A) and reduced the percentage of IFN-γ–producing effector
T cells compared with OVA-pulsed DCs that did not differentiate
naive T cells into Foxp3+ T cells but into IFN-γ–producing
effector T cells instead (Fig. 1A). These data were further
strengthened by reduced TNF and IFN-γ levels in supernatants
from Sia-OVA–pulsed DC cocultures (Fig. 1B). Comparable re-
sults were obtained using bone marrow-derived DCs (BMDCs)
(Fig. S2A). Functional analysis of the induced Foxp3+CD4+ T cells
revealed the presence of suppressive properties (Fig. 1C). Addi-
tion of T cells primed with Sia-OVA–loaded DCs markedly
inhibited the proliferation of carboxyfluorescein succinimidyl
ester (CFSE)-labeled responder T (Tresp) cells: only a few cells
underwent one to two divisions, and the majority did not divide
(Fig. 1C). In contrast, CD4+ T cells primed with OVA-pulsed DCs
(Tova cells) did not inhibit the proliferation of Tresp cells.
Under these conditions, and similarly to control cultures to
which no T cells were added, Tresp cells were able to undergo up
to five cell divisions.
Similarly, sialylation of MOG35–55, a well-known target of
autoreactive T cells in experimental autoimmune encephalomyeli-
tis (EAE), a murine model of multiple sclerosis (22), transformed
this peptide into a tolerogenic antigen. DCs pulsed with α2,3- or
α2,6-Sia-MOG35–55 induced naive MOG-responsive CD4+ 2D2
T cells (23) to express Foxp3 and prevented differentiation into
IFN-γ–producing effector T cells (Fig. 1D and E). Notably, CD4+ T
cells primed by Sia-MOG35–55 do not produce more IL-10 than
MOG35–55–loaded DCs (Fig. 1E). Because both α2,3- and α2,6-
linked Sia-antigens evoked equivalent tolerogenic responses, only
the data for α2,6-linked Sia-antigens, designated Sia-OVA or
Sia-MOG35–55, are shown for the remainder of the study.
Sia-OVA had comparable effects on naive T-cell polarization
using BMDCs isolated from BALB/c mice as C57BL/6-derived
DCs: 16% of DO11.10 T cells cocultured with Sia-OVA-BMDCs
were committed to the Foxp3+ lineage, whereas almost fivefold
fewer T cells became Foxp3+ when cocultured with OVA-loaded
BMDCs (Fig. 1F). DO11.10 T cells primed with OVA-loaded
BMDCs became committed to the IFN-γ–producing Th1 lineage
(8.5%; Fig. 1F). These data indicate that sialylated antigens
induced the maturation of Foxp3+ T cells irrespective of a Th1-
or Th2-prone microenvironment. Using CD4+ T cells from
Fig. 1. Sia-OVA promotes DC-mediated Treg-cell differentiation and pre-
vents effector T-cell generation. (A) Foxp3 and IFN-γ expressed by OT-II
T cells cocultured with OVA-, α2,3-Sia-OVA–, or α2,6-Sia-OVA–loaded splenic
DCs. The percentage of positive cells is indicated (n = 5). (B) IFN-γ and TNF in
supernatants of DC-differentiated OT-II T cells (mean ± SEM; n = 5). (C) Sup-
pressive activity of T cells primed with OVA-, α2,3-Sia-OVA–, or α2,6-Sia-OVA–
loaded DCs in a coculture with CFSE-labeled CD4+ Tresp cells (mean frequency
Tresp cells/division ± SEM; n = 2). (D) Foxp3 expression in 2D2 T cells differenti-
ated byMOG35–55–, α2,3-Sia-MOG35–55–, or α2,6-Sia-MOG35–55–loaded DCs (n = 3).
(E) TNF and IL-10 in supernatants of DC-differentiated 2D2 T cells (mean ± SEM;
n = 3). (F) Foxp3 and IFN-γ expression by DO11.10 CD4+ T cells upon coculture
with Sia-OVA– or OVA-loaded DCs. The percentage of positive cells is in-
dicated (mean ± SEM; n = 2). (G) Naive CD4+ 2D2 and OT-II T cells were
cocultured with DCs loaded with different antigens. The percentage of
Foxp3+ and IFN-γ+ T cells is depicted (mean ± SEM; n = 2). ***P < 0.001;
**P < 0.01; *P < 0.05.
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DO11.10×Rag−/− mice, we established that the Sia-OVA-DC–
induced Foxp3+CD4+ T cells were de novo-generated (Fig. S2B).
We next assessed whether the immunosuppressive properties
gained by DCs upon internalization of sialylated antigens are
antigen-specific or whether these DCs become broad immuno-
suppressive and also silence unrelated T-cell responses. Hereto,
DCs loaded with Sia-OVA and nonmodified MOG35–55 were
subsequently cocultured with purified CD4+ 2D2 T cells. As a
control, DCs were loaded with OVA and MOG or cocultured
with naive CD4+ OT-II T cells. Clearly, 2D2 T cells are not
polarized into Foxp3+ T cells by DCs pulsed with MOG and the
nonrelated Sia-OVA (Fig. 1G). The 2D2 T cells become IFN-
γ–producing effector T cells, similarly as when encountering DCs
pulsed with MOG35–55 only (Fig. 1E). Only OT-II T cells become
tolerized when encountering Sia-OVA–pulsed DCs, even when
these DCs internalized additional nonmodified antigens. To-
gether, these data reveal that uptake of sialic acid-modified an-
tigens by DCs results in the generation of tolerogenic DCs that
promote de novo Treg-cell induction and prevent effector T-cell
generation in an antigen-specific fashion.
Induction of Immune Tolerance Is Specific for Sialic Acid Carbohydrate
Structures.Given these specific tolerogenic effects of Sia-antigen–
loaded DCs on T cells in vitro, we next examined whether
administration into C57BL/6 mice also resulted in immune tol-
erance in vivo. Indeed, adoptive transfer of Sia-OVA–pulsed DCs
into C57BL/6 mice before immunization significantly reduced
IFN-γ–producing CD4+ and CD8+ T-cell numbers, which was
mirrored by low amounts of TNF and IFN-γ in the culture
supernatants of ex vivo-restimulated splenocytes (Fig. S3 A–D).
These effects were not induced by injecting OVA-pulsed DCs.
Importantly, the reduction in effector T-cell numbers in Sia-
OVA-DC–injected mice was accompanied by significantly higher
frequencies of Foxp3+CD4+ T cells (Fig. S3E). Thus, DCs that
have internalized sialylated antigens also mediate T-cell tolerance
in vivo. Because these data confirmed that in vitro-generated Sia-
OVA–loaded DCs maintain the capacity to induce suppressive
Treg cells in vivo, we continued to investigate whether adminis-
tration of Sia-OVA could modulate endogenous DCs. For this
purpose, C57BL/6 mice were injected with Sia-OVA 1 wk before
OVA immunization. Pretreatment of the mice with Sia-OVA
dampened subsequent induction of effector T-cell formation, as
indicated by the lower proportions of IFN-γ–producing CD8+
and CD4+ T cells detected ex vivo (Fig. 2 A and B). This in-
hibitory effect was not observed in mice that received OVA or
PBS. Notably, inhibition of effector T-cell expansion in mice
injected with Sia-OVA was accompanied by a higher frequency
of Foxp3+CD4+ T cells (Fig. 2C). Thus, DCs also become tol-
erogenic in vivo upon uptake of Sia-OVA, resulting in Treg-cell
expansion and effector T-cell dampening.
DCs Become Tolerogenic upon Internalization of Sialylated Antigens.
Induction of CD4+ Treg cells is known to predominantly occur
after exposure of naive CD4+ T cells to low concentrations of
antigens (24). However, sialylation of OVA did not hamper
OVA uptake by DCs (Fig. 3A). In fact, higher amounts of Sia-
OVA than OVA were taken up by DCs. Although DCs loaded
with very low amounts of Sia-OVA (i.e., ≤5 μg/mL) did not
promote Foxp3+CD4+ T-cell induction to a greater extent than
OVA-loaded DCs, a clear inhibition of effector T-cell generation
was observed with these low concentrations of antigen (Fig.
S4A). The effects observed on T-cell responses were highly
specific for sialic acids. Whereas GlcNAc modification improved
internalization of OVA (Fig. S4B and ref. 25) similar to Sia-
OVA, DCs loaded with mannose receptor targeting GlcNAc-
OVA promoted Th1 cell skewing and not Treg-cell induction
(Fig. S4B). Together, these data reveal that the induction of dual
tolerogenic features on DCs is specific for sialylated antigens.
Because DCs are key orchestrators of T-cell responses, we fur-
ther examined the effects of Sia-antigen internalization on the
instructive signals DCs provide to T cells. We observed that
these DCs secreted lower amounts of proinflammatory IL-6 and
TNF than DCs loaded with OVA (Fig. 3B). To assess whether
the tolerogenic effects of Sia-OVA–loaded DCs are mediated via
soluble factors, OVA-loaded DCs and naive OT-II T cells were
separated from Sia-OVA–loaded DCs using Transwell cham-
bers. In this case, OVA-loaded DCs did not acquire tolerogenic
and suppressive effects during T-cell differentiation (Fig. 3C).
Fig. 2. Sia-OVA induces tolerance and prevents the effector immune response
in vivo. C57BL/6 mice received 50 μg of Sia-OVA or OVA 1wk before sensitization
with OVA/poly(I:C)/anti-CD40. Frequencies of IFN-γ+CD8+ T cells (A), IFN-γ+CD4+
T cells (B), and Foxp3+CD4+T cells (C) among total splenocytes were determined
by flow cytometry. Dots represent individual mice (n = 7/group; bars indicate the
median). *P < 0.05; ***P < 0.001; ns, not significant.
Fig. 3. Sia-OVA-DC–mediated Treg-cell generation depends on antigen
dose and soluble factors. (A) Binding/uptake of Dylight549-labeled Sia-OVA
or OVA by DCs analyzed using flow cytometry (n = 3). (B) Secretion of TNF
and IL-6 by DCs incubated with OVA/LPS or Sia-OVA/LPS (mean ± SEM; n = 5).
(C) Frequency of IFN-γ+ OT-II cells after differentiation by DCOVA (lower
wells) in the presence or absence or Sia-OVA–loaded DCs in the top well of
Transwells (mean ± SEM of triplicates; n = 4). (D) IFN-γ+ OT-II T-cell fre-
quencies induced by BMDCs loaded with OVA, Sia-OVA, or a mixture of OVA
and sialic acids (mean ± SEM; n = 3). (E) Mean fluorescence intensity (MFI) of
bound and/or internalized Dylight549-labeled Sia-OVA or OVA by WT and
Siglec-E−/− DCs. (Means ± SEM; n = 4). (F) Foxp3 and IFN-γ expression in OT-II
T cells differentiated by antigen-loaded WT or Siglec-E−/− BMDCs (n = 2).
***P < 0.001; **P < 0.01.
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These data suggest that Sia-antigen–loaded DCs mediate toler-
ance in a cell–cell contact-dependent fashion. Notably, DCs only
gained tolerogenic properties when sialic acids were covalently
coupled to OVA and not when the sialic acids and OVA were
provided separately to DCs (Fig. 3D). Thus, although our data
demonstrate that antigens modified with sialic acids are effi-
ciently taken up by DCs, it remained unclear how these Sia-
antigens relay tolerogenic signals into DCs. We hypothesized
that siglecs may play a role in the binding and internalization of
Sia-OVA, as well as potentially triggering a signaling cascade
that induces modulation of the DC function (21).
Because the CD33-related Siglec-E is expressed on immature
murine DCs and is known to preferentially bind α2,3- and α2,6-
linked sialic acids (21), we investigated whether Siglec-E could
be the receptor on immature murine DCs that binds Sia-OVA.
Comparison of the binding and uptake of Sia-OVA by Siglec-E−/−
DCs and wild-type (WT) DCs revealed that both processes were
substantially reduced in Siglec-E−/− DCs (Fig. 3E). Furthermore,
the absence of Siglec-E on DCs profoundly arrested Treg-cell
induction in response to Sia-OVA (Fig. 3F): 15% of CD4+ T
cells differentiated into Foxp3+ T cells when cocultured with Sia-
OVA–loaded WT DCs compared with only 0.5% in cultures
containing Sia-OVA–loaded Siglec-E−/−DCs. Moreover, Siglec-E−/−
DCs did not prevent the generation of IFN-γ–producing effector
CD4+ T cells. In fact, Siglec-E−/− DCs loaded with either native
OVA or Sia-OVA equally skewed naive CD4+ T cells toward IFN-
γ–producing effector cells (i.e., 13% vs. 11%, respectively; Fig. 3F).
To rule out that an intrinsic defect of Siglec-E−/− DCs to promote
Treg-cell induction underlies the failure of Siglec-E−/− DCs to in-
duce Treg cells in response to Sia-antigen, we treated immature
Siglec-E−/− DCs with TGF-β or IL-10 for 24 h while loading with
OVA before coculture with naive CD4+CD62LHigh OT-II cells
(26). Analysis of Foxp3 expression showed that cocultures with
Siglec-E−/− DCs contained comparable frequencies of Foxp3+
CD4+ T cells as those with WT DCs (Fig. S4C), indicating that
Siglec-E−/− DCs are able to induce Treg cells similar to WT DCs.
We next investigated the possibility that native and sialylated
antigens might follow a different intracellular route, conse-
quently affecting presentation in MHC molecules and T-cell
activation. We therefore used imaging flow cytometry, a method
that allows high-throughput image analysis of cell in flow with
near-confocal resolution, to analyze the intracellular routing of
fluorescent labeled Sia-OVA and compare it to the routing of
native OVA. Costaining with markers for early endosomal
(EEA-1) (open bars) and lysosomal (LAMP-1) (solid bars)
compartments illustrated the presence of both Sia-OVA and
OVA within late endosomes/lysosomes 2 h after pulse as indicated
by the higher colocalization score with LAMP-1 than with EEA-1
(Fig. S5 A and B). Moreover, the percentage of cells with a high
OVA–LAMP-1 colocalization was roughly four times higher than of
cells with high OVA–EEA-1 colocalization (Fig. S5C). Colocaliza-
tion of Sia-OVA (red) with EEA-1 (green) and LAMP-1 (blue) was
additionally analyzed using a confocal laser-scanning microscopy
(CLSM). The 3D rendering of a 20-μm Z-stack clearly showed
the lack of association of OVA with early endosomes but the
enclosure of OVA within LAMP-1 positive vesicles (Fig. S5 D
and E). Thus, these data show that sialylation does not affect the
intracellular routing of antigens. Moreover, the fact that both
Sia-OVA and native OVA end up in the compartment that
generates MHC-II–binding peptides is in line with our finding
that CD4+ T-cell proliferation induced by Sia-OVA–loaded DCs
is comparable to that of OVA-loaded DCs (Fig. S5F). Together,
these data imply that Sia-antigens predominantly impose tol-
erogenic function on DCs via its interaction with Siglec-E on the
DC surface.
Sia-Antigen also Relays Tolerogenic Properties to DCs Under
Inflammatory Conditions. In the experiments described above,
DCs were modulated by sialylated antigens under homeostatic
conditions. To determine whether Sia-OVA also imposes tol-
erogenic function on DCs under inflammatory conditions, as
occurs during infections or in the early stages of neoplasia, we
assessed naive CD4+ T-cell differentiation by DCs pulsed with
Sia-OVA or Sia-MOG35–55 in the presence of LPS. Whereas
naive CD4+ T cells markedly differentiated into effector T cells
when primed with OVA/LPS or MOG35–55/LPS–pulsed DCs, the
ability to induce Treg cells and control effector T-cell generation
was maintained by Sia-antigen/LPS–loaded DCs (Fig. 4 A and
B). Also, the ability of CD8+ T cells to expand and become lytic
effectors, as shown by IFN-γ and granzyme B production, was
significantly reduced when DCs had internalized sialylated an-
tigens (Fig. 4 C and D), indicating a strong inhibitory effect
of sialylated antigens on the capacity of DCs to initiate cytotoxic
T lymphocyte (CTL) responses. Sia-OVA–loaded DCs also
dampened effector T-cell formation when cultured at a 1:1 ratio
with OVA-loaded DCs (Fig. 4E). These findings suggest that
sialylation of antigens could also be exploited to dampen existing
effector T cells. We therefore generated Th1 and Th17 cells
from naive 2D2 CD4+ T cells in vitro and observed that secretion
of effector cytokines by Th1 and Th17 cells was significantly re-
duced when encountering Sia-MOG35–55–loaded DCs but not
when reactivated by MOG-loaded DCs (Fig. 4F). To examine
whether Sia-antigens could inhibit MOG-specific effector T cells
induced upon the in vivo induction of EAE, we restimulated
splenocytes from mice with different EAE clinical scores, rep-
resenting different stages of effector T-cell number and activity,
Fig. 4. Sia-antigen also modulates DCs in an inflammatory environment.
DCs were loaded with antigens in the presence of LPS and cocultured with
OT-II or OT-I T cells. (A) Flow cytometric analysis of Foxp3 and IFN-γ expression;
the percentage of positive cells is indicated. (B) IFN-γ produced by 2D2 T cells
cocultured with DCs pulsed with MOG35–55/LPS, α2,3-Sia-MOG35–55/LPS, or
α2,6-Sia-MOG35–55/LPS (mean ± SEM; n = 3). CFSE-labeled OT-I T cells cocul-
tured with Sia-OVA/LPS or OVA/LPS–loaded DCs. (C and D) Percentages of
divided cells (C) and of IFN-γ+ and GrB+ OT-I cells (D) are shown (n = 3).
(E) Proportion of IFN-γ+CD4+ T cells in cultures with DCs loaded with Sia-OVA
or OVA mixed 1:1 with DCOVA. Control cultures contain only DCSia-OVA or
DCOVA. (F) IFN-γ or IL-17 production by in vitro-generated Th1 and Th17 cells
after reactivation by antigen-loaded DCs. (G and H) Ex vivo restimulation of
spleens from mice induced for EAE with Sia-MOG35–55–loaded (black bars) or
MOG35–55–loaded (gray bars) DCs. Medium-treated DCs (white bars) and
spleens of naive mice were assessed as controls. Four days later, MOG-
specific T-cell proliferation (G) and IFN-γ in culture supernatants (H) was
determined (means ± SEM; n = 3 mice/condition). ***P < 0.001; **P < 0.01;
*P < 0.05.
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with Sia-MOG– or MOG35–55–loaded DCs. MOG35–55–loaded
DCs induced ex vivo proliferation and IFN-γ production by
splenocytes collected from mice that were at the onset of disease
(score 1) or at a more severe phase of the disease (scores 2 or 3).
Notably, these processes were significantly suppressed when us-
ing Sia-MOG35–55–loaded DCs (Fig. 4 G and H). These data
indicate that sialic acid-modified antigens instruct DCs in an
antigen-specific tolerogenic program, reducing inflammatory
CD8+ and CD4+ T-cell responses.
Discussion
Here, we show, for the first time to our knowledge, that DCs
become tolerogenic upon uptake of soluble sialylated antigens.
Moreover, we provide evidence for induction of antigen-specific
immune tolerance under inflammatory conditions using sialylated
antigens. We observed that under inflammatory conditions, ef-
fector T-cell functions were also dampened by Sia-antigen–loaded
DCs. Importantly, under these circumstances Sia-antigen–loaded
DCs retained the capacity to polarize naive CD4+ T cells toward
Treg cells. To the best of our knowledge, this tolerizing effect
under inflammatory conditions has not been demonstrated for
other tolerizing compounds. The possibility of inducing tolerance
in vivo in an antigen-specific manner via this new strategy of sialy-
lation of antigens may open up new avenues for treating patients
who suffer from unwanted immune reactions such as autoimmunity
and allergies.
Tolerogenic DCs, either occurring in vivo or generated in vitro,
are characterized by an antiinflammatory phenotype attributable to
low expression of costimulatory molecules and the ability to pro-
mote Treg-cell induction. Although uptake of Sia-antigen by DCs
in vitro did not result in expression of surface markers associated
with “classic” tolerogenic DCs, DCs are clearly tolerogenic in
function upon internalization of sialylated antigens. We pre-
viously observed a similar absence of clear effects on the phe-
notype of human monocyte-derived DCs after incubation with
the highly sialylated pathogen Neisseria gonorrhea, although
T-cell polarizing capacity was affected (16, 27). Despite producing
lower amounts of the proinflammatory cytokines IL-6 and TNF,
we did not observe significant differences in the quantity of IL-10
or TGF-β produced by Sia-OVA–loaded DCs compared with
OVA-loaded DCs. Therefore, it is possible that Sia-OVA–pulsed
DCs induce Treg-cell induction and prevent effector T-cell gen-
eration via cell surface receptor–ligand interactions, rather than
secretion of antiinflammatory cytokines. This possibility is further
substantiated by our findings that Sia-OVA–loaded DCs did not
confer tolerogenic capacity onto CD4+ T cells when physically
separated or when the supernatant of Sia-OVA–loaded DCs was
used to treat OVA-loaded DCs.
Our findings indicate that the differentiation of naive
CD4+CD25− T cells into Treg cells and reduced generation of
effector IFN-γ+ T cells by Sia-OVA–pulsed DCs were not de-
pendent on the mouse strain, because DCs and T cells from both
C57BL/6 and BALB/c mice underwent equivalent responses.
Additionally, we even observed de novo Treg-cell generation
using naive CD4+ T cells from DO11.10×Rag−/−mice, which lack
natural Treg (nTreg) cells. However, we anticipate that DCs
tolerized by the uptake of Sia-antigen in vivo may also propagate
nTreg cells, because the detection of Foxp3+CD4+ T cells does
not discriminate between induced Treg (iTreg) cells and nTreg
cells. Nevertheless, the net result of Sia-antigen internalization
by DCs is the formation of increased numbers of T cells with
suppressive capacity that can inhibit detrimental effector T-cell
responses. In this process, Siglec-E plays an important role. In
fact, our data indicate that DCs are endowed with tolerogenic
characteristics via Siglec-E signaling upon internalization of
sialylated antigens. This finding is underscored by our observa-
tions that intracellular trafficking of antigens is not altered by
sialylation of antigens and that the presence of Siglec-E is re-
quired on DCs to induce Treg cells in response to Sia-antigens.
Besides affecting CD4+ T-cell responses, DCs loaded with
antigens modified with sialic acids also strongly restrained CD8+
T-cell responses. Both the expansion of CD8+ T cells as well as
the acquisition of cytotoxic effector functions was significantly
dampened, even under inflammatory conditions. Similarly, re-
duced CTL generation was observed in vivo when pretreating
mice with Sia-antigen or Sia-antigen–loaded DCs. How CD8+
T-cell responses are regulated in vivo by Sia-antigen pretreatment
is unclear. The CD8+ T-cell responses can either be controlled by
Sia-antigen–induced Treg cells or via direct effects of the Sia-
antigen–tolerized DCs, as shown in vitro. Because autoreactive
CTLs have been shown to contribute to the pathogenesis in type
1 diabetes and multiple sclerosis (28–31), treatment with sialylated
antigens could thus also be effective to dampen these pathologies.
CTLs also play crucial functions in the immune response
against viral infections. However, certain viruses such as herpes
simplex virus (HSV)-1 and -2 adopt latency as a strategy to evade
immune defense and persist in the host (32). Infections caused
by these viruses are characterized by low antigen expression and
a low level of CD8+ T-cell activation (33). Because high levels of
sialylated antigens have been found on the envelope glycopro-
teins of HSV-1/-2, it can be hypothesized that sialic acids on
HSV contribute to HSV immune escape by tolerizing DCs. Al-
though the focus of the present study was to examine the effect
of sialylated antigens on DCs and T-cell responses, B-cell re-
sponses may also be modulated. Liposomes coated with high-
affinity sialic acid derivatives that target CD22 have been shown
to induce B-cell tolerance (34).
Many siglecs act as negative regulators of immune responses
via the expression of ITIM motifs in their cytoplasmic tails.
Therefore, it is likely that the observed tolerogenic effect of Sia-
antigen results from interaction of Sia-antigen with siglec re-
ceptors on DCs. Our studies showed a significant reduction in
the binding and uptake of Sia-OVA by Siglec-E−/− DCs and,
concomitant, drastic inhibition of Treg-cell generation. This
finding suggests a relevant role for the Siglec-E receptor in the
interaction of Sia-antigens with DCs. Moreover, in view of these
findings, Sia-antigen–mediated Treg-cell induction and T-effec-
tor inhibition may occur via two different modes, with Siglec-E
mainly implicated in Treg-cell polarization. Loading WT DCs
with low concentrations of Sia-OVA antigen did not lead to
enhanced generation of Treg cells but still dampened effector
T-cell generation. It can be speculated that low antigen con-
centrations do not evoke clustering of Siglec-E, which is neces-
sary to relay intracellular ITIM signaling (21).
In healthy individuals, the most important role of Treg cells is
to maintain immune tolerance to self- and innocuous exogenous
antigens as well as the intestinal microflora to prevent the devel-
opment of autoimmune and allergic diseases (35). Defects in Treg-
cell number and/or function have been shown to contribute to
autoimmune diseases (4). Thus, therapies directed at resolving Treg-
cell defects have the potential to prevent and also cure such diseases.
Modification of specific antigens using sialic acids has a
number of advantages over current therapeutic strategies aimed
at establishing large cohorts of Treg cells: this method provides
DCs with a dual-tolerogenic function, because in addition to
induction of Treg cells, these DCs simultaneously inhibit the
generation of IFN-γ–producing T cells. Thus, using sialylated anti-
gens as a therapy may directly dampen excessive inflammation, a
process that occurs during autoimmunity. Furthermore, in contrast
to current adjuvant approaches such as administration of retinoic
acid or TGF-β, nonspecific suppression is minimized, because the
specific antigen is directly modified with sialic acids.
Moreover, we provide evidence for induction of antigen-spe-
cific immunotolerance under inflammatory conditions using
sialylated antigens. Importantly, under these circumstances Sia-
antigen–loaded DCs retained the capacity to polarize naive
CD4+ T cells toward Treg cells. To the best of our knowledge,
this sustained antigen-specific tolerizing effect has not been
demonstrated for other tolerizing compounds.
In conclusion, our data demonstrate that sialylation alters the im-
munogenicity of an antigen and provides a novel way to induce tol-
erogenic DCs for the treatment of autoimmune diseases and allergies.
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Experimental Procedures
Mice. C57BL/6 mice were used at 8–12 wk of age. OT-II, DO11.10,
DO11.10×Rag2−/−, and 2D2 TCR transgenic mice were bred in the animal
facilities of VU Medical Center (VUmc), Erasmus University Medical Center
(Erasmus MC), and the TWINCORE Institute under specific pathogen-free
conditions. All experiments were approved by the Animal Experiments
Committee of the Erasmus MC and VUmc and performed in accordance with
national and international guidelines and regulations.
Dendritic Cells. Spleens from C57BL/6 mice were enriched for CD11c+ cells by
magnetic separation according to the manufacturer’s protocol (Miltenyi
Biotec). BMDCs were cultured from bone marrow of WT or Siglec-E−/− mice
as described by Lutz et al. (36) with minor modifications (25).
Antibodies. The phycoerythrin (PE)-labeled antibodies were anti-CD8b
(H35-17.2) and anti-CD4 (GK1.5); the APC-labeled antibodies were anti-
CD62L (MEL-14), anti-Foxp3 (FJK-169), and anti-IFN-γ (XMG1.2). Anti-CD62L
and –IFN-γ antibodies were purchased from BD Pharmingen (BD Biosciences);
others were obtained from eBiosciences.
Modification of Antigens with Sialylated Glycans. To obtain Sia-OVA and Sia-MOG,
maleimide-activated 6′-sialyl-N-acetyllactosamine (SLN306; Neu5Acα2,6Galβ1,4Glc;
DEXTRA Labs) and 3′-sialyl-N-acetyllactosamine (SLN302; Neu5Acα2,3Galβ1,4Glc)
were conjugated to thio-activated OVA (Calbiochem) and to MOG35–55 peptide,
which is described in detail in SI Materials and Methods.
Th-Cell Differentiation and Testing of Suppressive Capacity.Naive CD4+CD62LhiCD25−
T cells were purified from spleen and LN cell suspensions using the Dynal mouse
CD4+CD62L+ T-cell isolation kit II mouse (Miltenyi Biotec) or by sorting on a
MoFlo (DakoCytomation). Naive CD4+CD62L+CD25− T cells (5 ×104) were added
to wells containing DCs (1 × 104) that were pulsed with the indicated concentra-
tions of Sia-antigen or native antigen 3 h prior. After 2 d, 10 U/mL recombinant
mouse IL-2 (Invitrogen) was added, and T-cell polarization was evaluated on day 6
by intracellular staining for Foxp3 and IFN-γ following 5 h of restimulation with
phorbol 12-myristate 13-acetate (PMA) (30 μg/mL)/ionomycin (500 ng/mL; Sigma)
in the presence of Brefeldin A (5 μg/mL; Sigma). To determine whether Sia-OVA–
loaded DCs induce Treg-cell differentiation via a soluble factor, the cells were
cultured in 0.4-μm pore size Transwell plates (Millipore). Suppressive capacity of
Sia-OVA-DC–primed T cells was determined using 4-d cocultures with 1 × 104 OVA-
loaded DCs and CFSE-labeled responder OT-II T cells.
Cytokine Analysis. Cytokines were determined by cytometric bead arrays
(CBA) using the CBA Th1/2/17 kit and mouse inflammation kit (BD Biosci-
ences) or by ELISA using specific antibody pairs (eBiosciences) following the
manufacturers’ instructions.
In Vivo Treatment. For modulation of endogenous DCs, C57BL/6 mice were
injected i.v. with 50 μg of Sia-OVA or OVA and primed 1 wk later by s.c. in-
jection of 200 μg of OVA/25 μg of polyinosinic–polycytidylic acid [poly(I:C)]/
25 μg of anti-CD40. Seven days after priming, the mice were killed, and spleens
were analyzed for the frequency of Treg cells and effector T cells after
restimulation with either 2 μg/mL SIINFEKL or 200 μg/mL EKLTEWTSSNMEER
OVA peptides.
Confocal Microscopy and Imaging Flow Cytometry. Intracellular routing of
Sia-OVA or native OVA in DCs was analyzed confocal laser-scanning mi-
croscopy and ImageStream X (Amnis) imaging flow cytometer as described
in SI Materials and Methods.
Statistical Analysis. Prism 5.0 software (GraphPad) was used for statistical
analysis. The Student’s t test and one-way ANOVA with Bonferroni correc-
tion were used to determine statistical significance. Statistical significance
was defined as P < 0.05.
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